The results of this study showed that DLN metastasis is associated with some poor prognostic factors of PTC, including male sex, lager tumor size, other CLN metastasis, and LLN metastasis.
The strength of this study lies in the inclusion of only unilateral PTC patients as the study population. Besides, the relationship between DLN metastasis and tumor locations was also analyzed in this study. Moreover, the number of patients in the DLN positive group is the biggest compare with previous studies. There are also some limitations in the present study. First, this is a cross-sectional study without follow-up, which makes it impossible to determine whether DLN is a direct prognostic factor for unilateral PTC patients. Secondly, we are unable to know the state of lymphatic vessel invasion, which makes it impossible to analyze whether DLN metastasis is associated with lymphatic vessel invasion. Finally, we did not collect data of DLN size. Thus, it is impossible to analyze whether there exists a relationship between DLN size and DLN metastasis.
In previous studies, among patients with PTC, the detection rate of DLN and the rate of metastasis to DLN varies a lot (detection rate: 23% -74.6%, metastasis rate 8.2%-24.8%) [17–23]. In the present study, the detection rate of DLN was 31.5% and the rate of metastasis to DLN was 25.5%. Several studies have reported that DLN metastasis is associated with a poor prognosis of thyroid cancer[17–23]. The first published study evaluating the associations between DLN metastasis and prognosis of thyroid cancer found that DLN metastasis was significantly associated with larger tumor size and was highly predictive of metastasis in other lymph nodes[17]. Similarly, another study also reported that DLN metastasis was associated with extra-thyroid extension, and higher frequency of concomitant metastases in the lymph nodes[18]. A cohort study in 2012 reported that DLN metastasis was associated with multifocality of the tumor, lager tumor size, and higher frequency of lymphvascular invasion, capsular invasion, central metastasis and lateral metastasis[19]. In the present study, DLN metastasis was found to be associated with several adverse prognostic factors of PTC, including male sex, larger tumor size, higher proportion of positive lymph nodes in CLN (excluding DLN), higher rate of ETE and capsular invasion. All the results of the previous studies on DLN in thyroid cancer were summarized in supplementary table.
The DLN receives afferent lymphatic drainage from the isthmus and the upper lobes of the thyroid[24]. Therefore, there may exist an association between different tumor locations and DLN metastasis. Two previous studies have reported that tumors in the upper third and isthmus are related to DLN metastasis, but the sample size of DLN positive groups in these two studies is small and may affect the validity of the results [20, 25]. In this study, there were 133 DLN positive patients among all 522 included patients. Our results showed that PTC located in upper third thyroid was significantly associated with DLN metastasis. Previous studies have reported PTC in upper third thyroid as a risk factor of LLN metastasis [26, 27]. In this study, we found that DLN metastasis was associated with the existence of LLN metastasis, and patients with metastasized DLN had more metastasized LLN compared with patients with normal DLN. These findings further confirmed the links between DLN metastasis, location of PTC, and LLN metastasis.
Previous study seldom separate patients with unilateral and bilateral PTC. The present study narrowed down the study population to patients with unilateral PTC, which is the most commonly diagnosed type of PTC. Patients with unilateral PTC generally have a good prognosis with a five-year survival rate over 95% according to the SEER database. Despite the good prognosis, the locoregional recurrence rate of these patients is between 15–30% and the central compartment recurrence rate is between 5–20% in 5–10 years [28–30]. Lymph nodes metastasis is the most common pathway for metastasis in PTC. Prior studies have reported the metastasis rate of CLN was almost 50% for cN0 PTC patients, and it is 48.3% in our study. Although some reports suggested that CLN metastasis had no effect on the prognosis of PTC, others indicated that PTC patients with CLN metastasis have a poor prognosis, including higher rates of recurrence and distant metastasis, worse disease-free survival, and higher mortality [3, 31]. Thus, it is still under debate for CLN resection as an operation routine for all PTC patients. An optional challenge is to select patients who may benefit from the resection of CLN. The stepwise process of lymph node metastasis of PTC has been revealed by several studies, firstly to the tracheoesophageal groove nodes and pretracheal nodes, and subsequently to the lateral neck nodes [32, 33]. Paratracheal lymph node is usually the most common metastasis sites for PTC, followed by DLN and pretracheal lymph node [7]. DLN is located in the fascia above the isthmus of the thyroid gland between the cricoid and thyroid cartilage, so that the resection of DLN could be done at the early stage of the operation. Moreover, the resection of DLN is easy and safe and could hardly result in complications. Moreover, the fast-pathological feedback of DLN could be achieved within 30 minutes by frozen section examination during the operation. Given these advantages and the high frequency of concomitant metastasis in other CLNs when DLN is positive, it has been suggested that total thyroidectomy and CLN dissection should be the first-line treatment in PTC patients with DLN metastasis. The finding of the present study showed that among all patients with DLN metastasis, 81.2% of them were detected with metastases to the other central compartment lymph nodes, adding supportive evidence to this suggestion. The PPV of metastasized DLN for metastasized CLN is up to 81.2% in the present study. However, more observational studies are needed to further confirm the role of DLN in predicting CLN metastasis.